Please assess the completion status of the following clinical trial:

Trial Title: Spreading Depolarization and Ketamine Suppression

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* GCS \<8~* SAH or severe traumatic brain injury requiring craniotomy~* Consent obtainable (via legal representative)~* Ictus (bleed or injury) within 48 hours of enrollment~* Clinically appropriate for multimodality monitoring~Exclusion Criteria:~* Anticipated survival \<48 hours~* No craniotomy~* Infratentorial craniotomy only•Unable to obtain consent~* Absence of clinically used multimodality monitoring~* Prisoners~* Pregnant

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Ketamine first (Type: EXPERIMENTAL): Randomization to receive ketamine as first post-operative sedative in the Neuroscience Intensive Care unit. This group will cross-over to other sedation after 6 hours, then alternate every 6 hours between these groups during the entirety of invasive neuromonitoring.
- Other sedation (typically propofol) first (Type: EXPERIMENTAL): Randomization to receive sedative other than ketamine as first post-operative sedative in the Neuroscience Intensive Care unit. This group will cross-over to ketamine after 6 hours, then alternate every 6 hours between these groups during the entirety of invasive neuromonitoring.

Based on this trial design, predict the completion outcome and termination type (if applicable).